LILLY ELI & CO's ticker is LLY and the CUSIP is 532457108. A total of 2,904 filers reported holding LILLY ELI & CO in Q3 2023. The put-call ratio across all filers is 1.16 and the average weighting 0.8%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Peachtree Investment Partners, LLC | 31,383 | $16,856,677 | 8.60% |
| Trust Investment Advisors | 18,111 | $9,727,756 | 8.37% |
| COMGEST GLOBAL INVESTORS S.A.S. | 873,088 | $468,961,757 | 8.03% |
| Grey Street Capital, LLC | 25,420 | $13,653,964 | 7.82% |
| Styrax Capital, LP | 120,310 | $64,622,110 | 7.73% |
| Finer Wealth Management, Inc. | 17,943 | $9,637,518 | 7.71% |
| Providence Wealth Advisors, LLC | 12,931 | $6,855,780 | 7.65% |
| PFM Health Sciences, LP | 298,643 | $160,410,115 | 7.56% |
| BLACKHILL CAPITAL INC | 145,133 | $77,955,288 | 7.51% |
| Systematic Alpha Investments, LLC | 279,303 | $150,022,000 | 7.47% |
| SOROS CAPITAL MANAGEMENT LLC | 32,500 | $17,456,725 | 7.32% |
| Saturna Capital CORP | 760,233 | $408,343,951 | 7.22% |
| PERKINS CAPITAL MANAGEMENT INC | 13,032 | $7,000 | 6.94% |
| J.P. Marvel Investment Advisors, LLC | 56,355 | $30,269,962 | 6.52% |
| Kampmann Melissa S. | 12,393 | $6,656,652 | 6.42% |
| Metavasi Capital LP | 21,000 | $11,279,730 | 6.35% |
| BUILDER INVESTMENT GROUP INC /ADV | 30,055 | $16,143,442 | 6.34% |
| Codex Capital, L.L.C. | 18,150 | $9,748,910 | 6.29% |
| Mirova US LLC | 690,465 | $370,869,465 | 6.29% |
| JW Asset Management, LLC | 27,000 | $14,502,510 | 6.28% |
About LILLY ELI & CO
Lilly Eli & Co is a pharmaceutical company that has been in operation for over 140 years. The company is known for its innovative research and development of drugs that have helped millions of people around the world. The company's mission is to make life better for people by discovering and developing new medicines that improve their health and well-being.
Lilly Eli & Co has a strong pipeline of drugs that are in various stages of development. The company is focused on developing drugs for cancer, diabetes, and Alzheimer's disease. The company's research and development efforts have resulted in the development of several blockbuster drugs, including Cialis, Humalog, and Prozac.
The company's leadership team is made up of experienced professionals who are committed to the company's mission. The CEO, David Ricks, has been with the company for over 20 years and has a deep understanding of the pharmaceutical industry. The company's board of directors is also made up of experienced professionals who bring a wealth of knowledge and expertise to the company.
Lilly Eli & Co is committed to sustainability and has implemented several initiatives to reduce its environmental impact. The company has set ambitious goals to reduce its greenhouse gas emissions, water usage, and waste generation.
In conclusion, Lilly Eli & Co is a pharmaceutical company that has a long history of developing innovative drugs that improve people's lives. The company's strong pipeline of drugs and experienced leadership team make it a promising investment opportunity for stock market investors.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists LILLY ELI & CO's shareholders in Q3 2023. To view LILLY ELI & CO's shareholder history, click here.